These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 16237736)

  • 1. Characterization of serum biomarkers for detection of early stage ovarian cancer.
    Kozak KR; Su F; Whitelegge JP; Faull K; Reddy S; Farias-Eisner R
    Proteomics; 2005 Nov; 5(17):4589-96. PubMed ID: 16237736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of serum biomarkers for detection of early- and late-stage endometrial cancer.
    Farias-Eisner G; Su F; Robbins T; Kotlerman J; Reddy S; Farias-Eisner R
    Am J Obstet Gynecol; 2010 Jan; 202(1):73.e1-5. PubMed ID: 19766980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of serum biomarkers for detection of early-stage ovarian cancer.
    Nosov V; Su F; Amneus M; Birrer M; Robins T; Kotlerman J; Reddy S; Farias-Eisner R
    Am J Obstet Gynecol; 2009 Jun; 200(6):639.e1-5. PubMed ID: 19285648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population.
    Moore LE; Fung ET; McGuire M; Rabkin CC; Molinaro A; Wang Z; Zhang F; Wang J; Yip C; Meng XY; Pfeiffer RM
    Cancer Epidemiol Biomarkers Prev; 2006 Sep; 15(9):1641-6. PubMed ID: 16985025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of serum biomarkers of ovarian epithelial cancers based on 2-DE DIGE and MALDI TOF/TOF].
    Zhao Q; Duan W; Wu YM; Qian XH; Deng XH
    Zhonghua Zhong Liu Za Zhi; 2008 Oct; 30(10):754-8. PubMed ID: 19173805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology.
    Petri AL; Simonsen AH; Yip TT; Hogdall E; Fung ET; Lundvall L; Hogdall C
    Acta Obstet Gynecol Scand; 2009; 88(1):18-26. PubMed ID: 19023702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarker discovery for ovarian cancer using SELDI-TOF-MS.
    Zhang H; Kong B; Qu X; Jia L; Deng B; Yang Q
    Gynecol Oncol; 2006 Jul; 102(1):61-6. PubMed ID: 16403569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.
    Havrilesky LJ; Whitehead CM; Rubatt JM; Cheek RL; Groelke J; He Q; Malinowski DP; Fischer TJ; Berchuck A
    Gynecol Oncol; 2008 Sep; 110(3):374-82. PubMed ID: 18584856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum peptide/protein profiling by mass spectrometry provides diagnostic information independently of CA125 in women with an ovarian tumor.
    Callesen AK; Madsen JS; Iachina M; Vach W; Kruse TA; Jensen ON; Mogensen O
    Cancer Biomark; 2010; 6(2):73-82. PubMed ID: 20571233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer.
    Ahmed N; Oliva KT; Barker G; Hoffmann P; Reeve S; Smith IA; Quinn MA; Rice GE
    Proteomics; 2005 Nov; 5(17):4625-36. PubMed ID: 16220531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
    Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
    Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
    Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P
    Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer.
    Kong F; Nicole White C; Xiao X; Feng Y; Xu C; He D; Zhang Z; Yu Y
    Gynecol Oncol; 2006 Feb; 100(2):247-53. PubMed ID: 16229881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Identification of two potential serum biomarkers for ovarian cancer and clinical validation thereof].
    Wang Q; Zhang W; Li DR; Li L
    Zhonghua Yi Xue Za Zhi; 2008 Apr; 88(15):1012-6. PubMed ID: 18754431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer.
    Jackson D; Craven RA; Hutson RC; Graze I; Lueth P; Tonge RP; Hartley JL; Nickson JA; Rayner SJ; Johnston C; Dieplinger B; Hubalek M; Wilkinson N; Perren TJ; Kehoe S; Hall GD; Daxenbichler G; Dieplinger H; Selby PJ; Banks RE
    Clin Cancer Res; 2007 Dec; 13(24):7370-9. PubMed ID: 18094419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B7-H4 is over-expressed in early-stage ovarian cancer and is independent of CA125 expression.
    Simon I; Katsaros D; Rigault de la Longrais I; Massobrio M; Scorilas A; Kim NW; Sarno MJ; Wolfert RL; Diamandis EP
    Gynecol Oncol; 2007 Aug; 106(2):334-41. PubMed ID: 17498784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteomic identification of salivary transferrin as a biomarker for early detection of oral cancer.
    Jou YJ; Lin CD; Lai CH; Chen CH; Kao JY; Chen SY; Tsai MH; Huang SH; Lin CW
    Anal Chim Acta; 2010 Nov; 681(1-2):41-8. PubMed ID: 21035601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
    Kang WD; Choi HS; Kim SM
    Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer.
    Nakae M; Iwamoto I; Fujino T; Maehata Y; Togami S; Yoshinaga M; Douchi T
    J Obstet Gynaecol Res; 2006 Jun; 32(3):309-14. PubMed ID: 16764622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.